Last reviewed · How we verify
NCT06802510
The Safety and Efficacy of Combined Microwave Ablation During Limb-sparing Surgery in High-risk Soft Tissue Sarcoma Patients
NA trial testing Microwave Ablation in Sarcoma in 44 participants. Completed in 31 December 2024.
31 December 2024
Quick facts
| Lead sponsor | Guangdong Provincial People's Hospital |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | other |
| Enrollment | 44 |
| Start date | 21 January 2018 |
| Primary completion | 31 December 2024 |
| Estimated completion | 31 December 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- Microwave Ablation
Conditions studied
- Sarcoma — all drugs for Sarcoma →
- Microwave — all drugs for Microwave →
- Ablation Techniques — all drugs for Ablation Techniques →
Sponsor
Guangdong Provincial People's Hospital
Who can join
Eligibility, any sex, with Sarcoma or Microwave. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Soft tissue sarcoma (STS) is a rare, aggressive malignancy with a high risk of recurrence when invading surrounding structures, and the optimal treatment strategy for safe surgical margin is still unclear. This study aimed to evaluate the safety and efficacy of combined local inactivation by ablation in STS during limb-sparing surgery in high-risk STS patients.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Limb-sparing surgery combined with local inactivation by ablation improves local control in soft-tissue sarcomas : a comparative study with long-term follow-up.
Yan Y, Huang C, Zhong G, Mengyu Y, et al · · 2025 · PMID 40967625 · DOI 10.1302/2633-1462.69.bjo-2025-0028.r1
Verify or expand the search:
- PubMed search for NCT06802510
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Microwave Ablation
Trials testing the same drug.
- NCT07404670 — Microwave Ablation for Treatment of Vascular Malformations: Efficacy and Safety · NA · not yet recruiting
- NCT07291973 — Clinical Investigation Evaluating the Performance, Safety and Clinical Benefit of the Endowave FlexAblate™ Microwave Abl · NA · recruiting
- NCT06426992 — Clinical Effectiveness of Microwave Ablation Using Starwave Microwave Generator for Hepatic Malignancies · NA · recruiting
- NCT06288620 — Microwave Ablation in the Treatment of Early-stage Unifocal Invasive Breast Cancer · NA · unknown
- NCT06128525 — Prostate Resection After Microwave Ablation (PRAMA) · NA · completed
Other recruiting trials for Sarcoma
Currently open trials in the same condition.
- NCT07402577 — Brief Title Mechanisms of Cancer-Related Pain and Opioid Use Among Adolescents and Young Adult Sarcoma Survivors: Pilot · recruiting
- NCT07501026 — Preoperative Spatially Fractionated Radiation Therapy (SFRT) in Soft Tissue Sarcoma (neoSFRT-SARC) · Phase 2 · recruiting
- NCT07359911 — Effect of A Multimodal Exercise Intervention on Chemotherapy Uptake in Newly Diagnosed Pediatric and AYA Sarcoma Patient · NA · recruiting
- NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT07222735 — Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory Sarcoma · Phase 1 · recruiting
Other Guangdong Provincial People's Hospital trials
Trials by the same sponsor.
- NCT07521605 — Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal Cancer · Phase 2 · not yet recruiting
- NCT07514611 — Weight Loss Via Intelligent Guidance in Patients With Coronary Heart Disease and Obesity: a Randomized Clinical Trial · NA · recruiting
- NCT07352930 — A Novel Intraoperative Fluorescence-guided System for Evaluating Margins During Breast-conserving Surgery for Breast Can · NA · not yet recruiting
- NCT07472478 — Phase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12 · Phase 2 · not yet recruiting
- NCT07483398 — RELIEF-PD: Crisugabalin for Nociplastic Pain in Parkinson's Disease · Phase 4 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06802510 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Guangdong Provincial People's Hospital
- Last refreshed: 31 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06802510.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing